INTRODUCTION
not only in the intracellular domains known to be involved in G protein activation, but also in transmembrane domains (TMDs) and even in some cases in extracellular domains.
Most of these residues have been proposed to participate in networks of intramolecular interactions, which stabilize the receptors in inactive conformations R. Disruption of these networks results in a conformational shift from R to R* (2, (10) (11) (12) (13) (14) (15) .
In the case of rhodopsin, a salt-bridge constraint between E113 3.28 in TMD-III and K296 7.43 in TMD-VII stabilizes the receptor in the R state (10) . Similar intramolecular interactions have been demonstrated for α 1A -adrenoceptors between D125 3.32 of TMD-III and K331 7.43 in TMD-VII.
Activation of this receptor is believed to result from the disruption of the D125 -K331 salt-bridge by the neurotransmitter biogenic amine that acts as counter-ion of the D125 (11) . However, this mechanism of receptor activation is likely to be specific for α 1B -adrenergic receptor since the K in TMD-VII is not conserved within related GPCRs sequences. sequence (cytoplasmic end of TMD-III) and a conserved Glu in the cytoplasmic end of TMD-VI (E268 6.30 in β2-adrenergic receptor) (13) . For several GPCRs, charge-neutralizing mutations of these residues increase constitutive activity by disrupting this lock (15) (16) (17) . In rhodopsin, similar disruption is observed following protonation of the Glu in the ERY sequence (equivalent to the DRY sequence) and another acidic residue that could be the conserved Glu of TMD-VI (18) . Taken together, these findings support the idea that the disruption of intramolecular interactions constitutes the receptor activation switch, although the precise residues involved in these interactions may vary between different receptors. Such an hypothesis is also supported by the observation that constitutively active receptors are characterized by structural instability (16, 19, 20) .
In contrast to the rapid progress in understanding molecular mechanisms underlying the transition from R to R*, mechanisms by which inverse agonists favor the conversion from R* to R (inactive conformation) remain unclear. An important observation was that mutations of residues that The mutants were generated by exchanging the endogenous residues to Alanine in the m5-HT 4 cells/ml) containing 10% dialyzed and decomplemented fetal bovine serum (dFBS) and plated on 10cm Falcon Petri dishes or into 12 wells clusters at the desired density.
Determination of cyclic AMP (cAMP) Production in Intact Cells.
Six hours after transfection, the surrounding cell media was exchanged for DMEM without dFBS with 2 mCi [was measured as described previously (22) .
Membrane Preparation and Radioligand Binding Assay.
Membranes were prepared from transiently transfected cells plated on 15-cm dishes and grown in DMEM with 10% dFBS for 6 h, followed by incubation for 20 h in DMEM without dFBS. The cells were washed twice in PBS, scraped with a rubber policeman, harvested in PBS, and centrifuged at 4°C (200g for 4 min). The pellet was resuspended in buffer containing 10 mM HEPES (pH 7.4), 5 mM EGTA, 1 mM EDTA, and 0.32 M sucrose, and homogenized 10 times with a glass-Teflon potter at 4°C. The homogenate was centrifuged at 20,000g for 20 min, and the membrane pellet was resuspended in 50 mM HEPES (pH 7.4; 5 mg of protein in1 ml of solution)
and stored at -80°C until use. 5-HT 4 receptor densities were estimated with the specific radioligand 
Data Analysis.
Using Kaleidagraph software, the dose-response curves were fitted according to the equation workstation. Although these models generated very similar molecular structures, the findings reported here are based on the model that returned the best 3-dimensional likeness of rhodopsin.
This model was submitted to energy minimization using the program Discover 3 and the CFF force field. Cα-trace was tethered by applying a force constant value of the quadratic potential of 100. A steepest descent followed by a conjugate gradient method then was applied until convergence with (26) is believed to make an ionic interaction with neurotransmitters protonated amine. As expected, 5-HT was completely unable to stimulate the D100A mutated receptor ( Fig.2A ), due to its loss of binding ( These data suggest that, the D100 3.32 A mutant has not lost the ability to be activated as long as the agonist is able to bind. When expressed at densities ranging from 200 up to 10000 fmol/mg protein, the basal level of cAMP synthesis of the D100A mutant was 1.5 -2-fold higher than that of WT. Receptor expression levels of WT or D100A were also not significantly different following transfection of 300 ng cDNA (1350± 60 and 1580±60 pmol/mg protein for WT and D100A, respectively).
Whereas, as already discussed, highly potent inverse agonists (RO116-0086, RO116-1148) blocked the WT constitutive activity, they were absolutely unable to inhibit basal constitutive activity of the D100A mutant (Fig.3A ). This effect is not unique to these two newly highly potent inverse agonists, similar results were obtained with the previously described 5-HT 4 receptor inverse agonists, GR The binding of these inverse agonists to the D100A mutant was confirmed by the capacity of these compounds to behave as antagonist of the BIMU 8 stimulated cAMP accumulation ( Fig.3 B-C).
The influence of receptor expression on inverse agonist activity was then analyzed. While the receptor constitutive activity increased as expected as a function of the receptor concentration, RO116-1148 remained totally inactive as inverse agonist on the D100A mutant (Fig.5B ). In comparison, its effect on WT receptor was constant whatever the receptor concentration (Fig.5A ).
Thus, a mutant was generated that was fully activated by but insensitive to inverse agonists in spite of the ability of these later to bind to the receptor.
D100
3.32 A mutation is a dominant mutation, which prevents the effect of inverse agonists whatever the level or nature of the constitutive activation of the
5-HT 4 receptor:
In a previous study we showed that either truncation of the C-terminal domain of 5-HT 4 receptor (∆327 7.70 ) or the A258 6.34 L mutation in the third intracellular loop elevated the constitutive activity relative to the WT 5-HT 4 receptor (21) ( 5-HT was inactive on these double mutants whereas, as on D100A, BIMU8 remained fully efficient (Fig.6 B) . Taken together, these results shown that the D100A+∆327 and D100A+A258L dual mutants were qualitatively similar in their pharmacological behaviour to the D100A mutant on its own. Thus, the D100A mutant is a "dominant" mutant. It blocked the effects of inverse agonists on constitutively activated 5-HT 4 receptors, whatever the nature or intensity of the constitutive activation.
Among other mutations leading to different constitutively active 5-HT4
receptors, mutations of two aromatic residues, F275A and W272A block
RO116-1148 inverse agonist activity:
We investigated the effects of mutation of other residues known to be involved in the binding of 5-
HT or the constitutive activation of the receptor ( Figure 7A ). The T134 4.38 A mutation is located in the second intracellular loop (T134 4.38 is a conserved threonine in many 5-HT receptors (27) ). The R118 3.50 A mutation is located at the putative interface between TMD-III and the i 2 loop (R118 residue belongs to the DRY sequence). In addition to the D100A mutant, four mutants were generated in the membrane-spanning regions. The S197 5.43 of TMD-V, which likely interacts via a hydrogen bond with the OH of 5-HT, was mutated into Ala (S197A). Two highly conserved aromatic residues of TMD-VI (F275 6.51 A and W272 6.48 A) (28) were mutated into Ala. The Asn residue in of TMD-VII (N308 7.49 ), which is conserved across the family 1 GPCRs, was mutated to
Asp.
The S197A, T134A and F275A mutants were similar to the WT receptor in their levels of constitutive activity. The N308D and R118A mutants had levels of constitutive activity, similar to that of D100A (Fig. 7B) . Of all the mutants investigated, we found only F275A to be similar to Competition binding studies with [ 3 H] GR113808 demonstrated that RO116-1148 binds to the W272A mutant (1.14 ±0.3 x 10 -9 M) with a very small decrease in affinity relative to WT ( Figure 8A ). In addition, the 5-HT-mediated cAMP accumulation at this W272A mutant was antagonized by RO116-1148 ( Figure 8B ).
Taken together, these results revealed that, two mutations (W272 6.48 A and F275 6.51 A), in addition to the D100 3.32 A mutation, inhibit the effects of inverse agonists on the 5-HT 4 receptor constitutive activity, but not the ability of these compounds to bind to the receptor.
Molecular modeling of the 5-HT 4 receptor
A model of the molecular structure of the 5-HT 4 receptor was developed, using a template based on the corresponding region of high structural resolution recently determined for rhodopsin ( Figure   9A ). With this model we aimed to investigate the relationships between the three residues ( D100 3.32 , F275 6.51 , W272 6.48 ) that were experimentally determined to contribute to the effects of inverse agonists. With this model we hoped to elucidate the relative positions of these three residues in three-dimensional space.
Using this model, the distances between D100 3.32 , W272 6.48 and F275 6.51 ) side chains were determined to range from 3 to 4 Angstroms ( Figure 9B ). In addition the side chains of F275 and W272 contribute to an aromatic cluster of π-interactions, similar to those described previously for catecholamine receptors (30) . The acidic side chain of D100 was found to be oriented towards the amine of W272 indole group, and might participate in a polar interaction that would be stabilized by the aromatic ring of the F275 residue that is predicted to reside immediately above it. The intramolecular interactions predicted by this model would be expected to be disrupted by the
DISCUSSION
One of the key findings of this study was the observation that the potent inverse agonists, RO116-0086 and RO116-1148, reverse basal levels of cAMP accumulation in WT but not the D100A mutant. In addition, these agents were ineffective following dual mutation of D100 synthetic ligand (31)). Since BIMU 8 was at least equi-potent and equi-effective at the D100A and WT receptor, we conclude that D100 3.32 is not involved in the conformational shifts that result in receptor activation, at least for this synthetic ligand. In contrast, D100 is essential for the shifts in receptor conformation that result in receptor inactivation by the studied inverse agonists.
The two-state model is now believed to be a simplification of a more general concept of allosteric equilibrium (7, 32, 33) . According to this concept, the receptor undergoes transitions between different allosteric states. Agonists preferentially stabilize different R* states, and consequently can stimulate different signal transduction pathways by " receptor trafficking" (7).
Our group previously showed that constitutively active 5-HT 4 receptor mutants (∆327 and A258L) have different R* conformations (20) .
A recent study on agonist-mediated changes in conformation of the G protein-coupling domain of β2-adrenoceptors found that conformations stabilized by full or partial agonists were different (14) . Therefore, it seems likely that the inactive R state is a heterogeneous population of different inactive conformations. Using this logic, the rhodopsin receptor, proposed to exist in at least three different states, might be expected to exist instead in at least three different populations of states. The "ground" silent state (Rg) of rhodopsin is stabilized by the inverse agonist, cis-retinal.
It is distinct from another low activity state, the ligand-free opsin state, R. The third state, metarhodopsin II, is characterized by being bound to all-trans-retinal, and is fully active (R*) (8, 34 ).
The activity of the R state was determined to be 10 -6 times lower than that of the R* state (34).
Stabilization of the Rg state by cis-retinal, the inverse agonist, is necessary for the physiological activity of rhodopsin as it enables the rod cell to operate as a single photon detector even in the presence of high levels of activated rhodopsin.
The findings of this study might be explained by applying the rhodopsin three-states model Inversely, the absence of constitutive activity and insensitivity to inverse agonists observed with the W272A mutant might indicate that this receptor exist predominantly in the Rg state. The observed agonist-mediated increases in cAMP accumulation demonstrate that this mutation does not interfere with agonist-mediated conversion from Rg to R* (Figure 8 ). The lack of effect of inverse agonists in the W272A mutant is possibly due to the very low levels of constitutive activity.
However, from separate studies in which basal cAMP accumulation is increased by the additional A258L mutation, the persistent insensitivity to inverse agonists supports the idea that the W272 We can apply the three states model to our observations with the D100A, D100A+∆327 and D100A+A258L mutants. Although these mutants had different levels of constitutive activity, they retained sensitivity to the agonist. This indicates that the D100A mutation does not impair the agonist-mediated transition to the R* conformation. Conversely, in these mutants the transition to the Rg state is no longer favored by inverse agonists. Similar logic might be applied to the influence of the F275A mutant on intramolecular interactions.
In dual mutation studies, the observed failure of the constitutively activating mutations, ∆327 or A258L, to overcome the insensitivity of D100A to inverse agonists suggests that the intramolecular interactions associated with activation of cAMP synthesis, and hence R*, are different from those associated with inactivation of cAMP synthesis and Rg.
It is now well established that TMD-III and TMD-VI play a crucial role in GPCR activation (2) . For many GPCRs, activation involves disruption of a network of interactions consisting of the (15) (16) (17) . Moreover, in studies of rhodopsin or β2-adrenoceptors, activation by site-directed labeling of residues on the cytoplasmic side of the TMDs III and VI strongly suggests that activation involves clockwise rotation and separation of TMD-III from TMD-VI (38,39).
The data presented in this study suggest that a different network of intramolecular interactions exists in the 5-HT 4 receptor between the D100 3.32 residue of TMD-III and the W272 6.48 and F275 6.50 residues of TMD-VI. This network underlies the actions of inverse agonists but not agonists. The resulting structural model of the 5-HT 4 receptor, presented in Fig 9A was based on the structure of the corresponding sequence of rhodopsin which has previously been elucidated (35). In this model, the side chains of residues D100 3.32 , W272 6 .48 and F275 6.51 are 3 -4 Angstroms apart. In addition, the aromatic cluster formed between the side chains of F275 and W272 has previously been described for other catecholamine GPCRs (40). Finally, we propose that a polar interaction between the acidic side chain of D100 and the amine of W272 is stabilized if the aromatic ring of F275 is localized immediately above it.
We hypothesize that the electrostatic influence of the aromatic W272 residue on its surroundings must be neutralized in order for the receptor to adopt the Rg conformation. This occurs when the W272 residue is engaged in the W272-D100-F275 network. Mutations of D100
and F275 to alanine explain the absence of effect of inverse agonists, and hence the failure to stabilize the W272-D100-F275 network that defines the Rg conformation, because under the alanine substitutions, neutralization of the electrostatic influence of W272 is no longer possible.
Using the same logic, we predict that the W272A mutation permanently neutralizes the electrostatic influence of the W272 thereby stabilizing the Rg state.
We propose that 5-HT 4 receptor inverse agonists described here, favor a D100 3.32 -F275 6.51 -W272 6.48 constraining network, which is not required for agonist activation. How this occur is a matter of speculation. One hypothesis is that the aromatic moiety of inverse agonists interact with hydrophobic residues of the network to favor the receptor constrain. Indeed, a shift in the position of the aromatic moiety of RO 116-0086 by adding a chloro and an amino substituents to give the SB 204070 compound, suppress the inverse agonist property of the drug.
Further studies may reveal the existence of analogous networks in other Family I GPCRs which would help to define the molecular determinants of inverse agonists. Exploration of such networks would provide a better understanding of the influences that govern conversion between different receptor conformations, and the effects of agonists, inverse agonists and antagonists in terms of their impact on the GPCR structure.
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